Trial Profile
A Phase II, Open-Label, Multi-Center Study to Evaluate the Safety, Pharmacokinetics, and Hematopoietic Stem Cell Mobilization of TG-0054 in Patients With Multiple Myeloma, Non-Hodgkin Lymphoma or Hodgkin Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Nov 2023
Price :
$35
*
At a glance
- Drugs Burixafor (Primary)
- Indications Stem cell mobilisation
- Focus Therapeutic Use
- Sponsors GPCR Therapeutics; TaiGen Biotechnology
- 23 May 2014 New trial record